Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
This study has been completed.
Integrated Therapeutics Group
Information provided by:
First received: July 31, 2006
Last updated: March 26, 2010
Last verified: March 2010
This study will hope to show that by relieving the participant's nasal symptoms of seasonal allergies using mometasone furoate nasal spray, the participant will obtain a better quality of night-time sleep, which in turn, causes less daytime sleepiness so that he/she can function productively during the day.
Seasonal Allergic Rhinitis
Drug: Mometasone Furoate Nasal Spray (MFNS)
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
||A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis
Primary Outcome Measures:
- Mean Change of the AM-PRIOR-reflective (Participant's Status Over the Previous 12 Hours) Total Nasal Symptoms Severity Score (TNSS) Averaged Over the Last 7 Days of Treatment From the Baseline Score. [ Time Frame: Average of the last 7 days of treatment ] [ Designated as safety issue: No ]
The TNSS score included the sum of nasal congestion/stuffiness, rhinorrhea/nasal discharge, sneezing, and nasal itching, each scored on a scale of 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The TNSS score could range from 0 to 12.
NOTE: Least square means and standard errors were obtained from an ANCOVA model with the treatment effect and the variable specific Baseline as a covariate.
- Mean Change From Baseline (Day 1/Visit 3) in the Sleep Problems Index II (SLP9) Score From the Medical Outcome Study Sleep Scale (MOS-SS) at the Day 29 Visit. [ Time Frame: 29 days ] [ Designated as safety issue: No ]
Following Visit 2 (Screening), at Baseline, Day 15, and Day 29 visits, participants needed to complete the MOS-SS questionnaire with scores from 1 = all of the time to 6 = none of the time, according to their frequency of occurrence during the previous week. The analysis endpoint MOS-SS Sleep Problems Index II (SLP9) score was derived from MOS-SS questionnaire and scaled from 0 = none of the time to 100 = all of the time.
NOTE: Least squares means and standard errors were obtained from an ANCOVA model with the treatment effect and the variable specific Baseline as a covariate.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2006 (Final data collection date for primary outcome measure)
Experimental: Mometasone Furoate Nasal Spray
Mometasone Furoate Nasal Spray 200 mcg, once daily.
Drug: Mometasone Furoate Nasal Spray (MFNS)
MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
Other Name: MFNS
Placebo Comparator: Matching placebo nasal spray
Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Must be >=18 years of age and older, of either sex, and of any race.
- Clinically symptomatic at Screening (Day -7 to -4)and at Baseline (Day 1)
- At Screening Visit, must have complaints of sleep disturbance while symptomatic with seasonal allergic rhinitis (SAR) and must have a score of 30 or greater for the Sleep Disturbance Sleep Scale (items 1,3,7 and 8)
- At the Baseline Visit, must have complaints of sleep disturbance and daytime somnolence while symptomatic with SAR and with a score of 30 or greater for the Sleep Problems Index II (SLP9) and 30 or greater for the Daytime Somnolence Sleep Scale (items 6, 9, and 11)
- Must have a 2-year or longer history of SAR occurring during the same season as the current study.
- Must have skin tests positive for outdoor allergens common in subjects with SAR prevalent during the time of this study, such as, trees, grasses, weeds, ragweed, and molds. The skin tests should be performed at Screening if not done within 12 months prior to the Screening Visit
- Must be free of clinically significant disease that would interfere with study evaluations
- Women of childbearing potential need to use a medically accepted method of birth control prior to Screening and during the study, or provide documentation of surgical sterilization. Women who are not sexually active at enrollment must consent to the use of a medically accepted method of birth control if/when they become sexually active during study participation.
- Female subjects of childbearing potential must have a negative urine pregnancy test at the time of enrollment at the Baseline Visit.
- Women who are pregnant, intend to become pregnant during the study, or are nursing
- Evidence of nasal polyps, deviated septum, or other intranasal anatomical obstruction(s) that would interfere with nasal airflow
- Acute or chronic sinusitis being treated with antibiotics and/or topical or oral nasal decongestants
- Acute respiratory infection within 2 weeks of the Screening Visit
- Diagnosis of clinically relevant sleep problems unassociated with allergies
- Complaints (within 12 months of the Screening Visit to their health-care provider) of difficulty sleeping or daytime sleepiness while not experiencing SAR symptoms, and continue with these complaints
- Snoring associated with an enlarged uvula or other upper airway pathology
- Had episodes of snoring associated with gasping or choking
- Awakened suddenly, on more than 1 occasion during the month preceding the Screening Visit, with a gasping or choking feeling
- Requires the use of oral appliances at night for bruxism (teeth gnashing) or temporomandibular joint problems
- Diagnosis of asthma with daytime and nighttime asthma symptoms not controlled by short-acting beta-2 adrenoceptor agonists
- Dependence on nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids.
- Currently undergoing a progressive course of immunotherapy (hyposensitization). Subjects on a regular maintenance schedule prior to the Screening Visit and who wish to remain on this schedule during the study are eligible for study inclusion; however, they may not receive hyposensitization treatment within 24 hours prior to any study visit
- Smokers or ex-smokers who have smoked within the previous 6 months
- Concomitant medical problem that may interfere with participation in the study, eg, repeated migraine episodes, uncontrolled convulsive disorders.
- Any of the following clinical conditions: Active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, systemic viral infections or ocular herpes simplex.
- Subjects participating in any other clinical study(ies).
- Subjects allergic to or with a sensitivity to the study drug or its excipients.
- Subjects who are night-shift workers or do not have a standard "asleep at night/awake during the day" cycle
No Contacts or Locations Provided
No publications provided
||Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 31, 2006
|Results First Received:
||February 18, 2010
||March 26, 2010
||Belgium: Federal Agency for Medicines and Health Products, FAMHP
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: The Italian Medicines Agency
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Russia: Pharmacological Committee, Ministry of Health
Spain: Spanish Agency of Medicines
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2014
Rhinitis, Allergic, Seasonal
Respiratory Tract Diseases
Immune System Diseases
Respiratory Tract Infections
Nervous System Diseases
Signs and Symptoms